Cipla USA Initiates Class II Recall of Cinacalcet Hydrochloride Tablets Over Nitrosamine Impurity Exceeding ADI Limits
Cipla USA, Inc. has initiated a Class II voluntary recall of 12,576 bottles of Cinacalcet Hydrochloride Tablets (90 mg, Lot 5PB0183) due to N-nitroso-cinacalcet impurity levels exceeding acceptable daily intake limits. This nationwide U.S. recall, effective November 14, 2025, underscores critical CGMP deviations impacting product safety and regulatory compliance for Cipla USA, Inc.
Recall Details: Nitrosamine Contamination in Cipla's Cinacalcet Hydrochloride Tablets
Cipla USA, Inc., based in Warren, NJ, has initiated a voluntary Class II recall of specific lots of its Cinacalcet Hydrochloride Tablets. This critical regulatory action, identified as recall number D-0226-2026, commenced on November 14, 2025, and remains ongoing. The primary reason cited for this recall is a significant Current Good Manufacturing Practice (CGMP) deviation: the presence of N-nitroso-cinacalcet, a nitrosamine impurity, at levels exceeding the acceptable daily intake (ADI) limits set by regulatory bodies. This directly impacts patient safety and product efficacy, necessitating immediate action from all stakeholders in the supply chain. Procurement directors must recognize that this impurity issue reflects a fundamental breakdown in quality control processes, demanding a thorough re-evaluation of Cipla USA's manufacturing oversight. For regulatory affairs heads, this event highlights the continuous scrutiny on nitrosamine impurities across the pharmaceutical industry, requiring robust testing and control strategies for all active pharmaceutical ingredients (APIs) and finished drug products. The affected product is Cinacalcet Hydrochloride Tablets, 90 mg, distributed in bottles containing 30 tablets each, under NDC 69097-412-02. Specifically, Lot 5PB0183, with an expiration date of January 31, 2027, is impacted, with a total of 12,576 bottles subject to this nationwide recall across the United States. This event underscores the imperative for stringent impurity profiling and control throughout the drug product lifecycle.
Impacted Product Profile: Cipla USA's Cinacalcet Hydrochloride Tablets
The recalled product, Cinacalcet Hydrochloride Tablets, is a human prescription drug administered orally. It is a generic version of a calcimimetic agent, indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, and for hypercalcemia in adult patients with parathyroid carcinoma. Cipla USA, Inc. holds Abbreviated New Drug Application (ANDA) 208915 for this product, signifying its approval by the FDA for marketing in the United States. The specific product NDCs involved are 69097-410, 69097-411, and 69097-412, with package NDCs including 69097-410-02, 69097-411-02, and 69097-412-02. The substance name is Cinacalcet Hydrochloride (UNII: 1K860WSG25). This recall directly impacts the availability of a critical medication for patients managing complex endocrine disorders. Supply chain VPs must immediately assess their inventory of Cipla USA's Cinacalcet Hydrochloride Tablets, particularly Lot 5PB0183, to prevent further distribution of contaminated product. Business development executives should evaluate the market implications, as a disruption in supply for a widely used generic can create immediate opportunities for competitors with compliant products. The presence of N-nitroso-cinacalcet above ADI limits is a serious quality concern, potentially leading to long-term health risks for patients, thus necessitating swift and decisive action from all parties involved.
Supply Chain Exposure: Managing Cinacalcet Hydrochloride Sourcing Risks
This recall of Cipla USA's Cinacalcet Hydrochloride Tablets presents immediate and significant supply chain exposure for distributors, pharmacies, and healthcare providers nationwide in the U.S. Procurement directors must identify all purchases of Lot 5PB0183 and initiate quarantine procedures, halting further distribution or dispensing. The 12,576 bottles recalled represent a tangible quantity that needs to be accounted for and returned, impacting inventory levels and potentially creating localized shortages. Downstream formulators or repackagers, if any, sourcing Cinacalcet Hydrochloride API from Cipla's manufacturing network would also need to conduct a thorough risk assessment, even if their specific finished products are not directly part of this recall. The underlying CGMP deviation related to nitrosamine formation suggests a systemic issue that could extend beyond this specific product lot. Regulatory affairs heads must advise their organizations on the implications of distributing or holding affected product, ensuring compliance with FDA recall procedures. Business development executives should monitor the market for potential supply gaps and strategic opportunities to support affected customers. The nationwide distribution pattern means that the impact is broad, requiring a coordinated response across diverse geographical regions within the United States. This event underscores the critical need for robust supplier qualification programs that include rigorous audits of quality systems and impurity control strategies, particularly for nitrosamines.
Mitigating Risk: Identifying Alternative Cinacalcet Hydrochloride Sources
Given the recall of Cipla USA's Cinacalcet Hydrochloride Tablets, procurement teams must immediately prioritize identifying and qualifying alternative suppliers to ensure continuity of supply for this essential medication. While the ChemLifeIntel Knowledge Graph does not currently list specific alternative suppliers for Cinacalcet Hydrochloride, this absence itself highlights the critical need for proactive market intelligence and due diligence. Supply chain VPs should initiate a rapid assessment of the global API market to identify manufacturers with established track records of compliance and robust nitrosamine control strategies. Key considerations for qualification timelines will include evaluating manufacturing sites for adherence to international CGMP standards, reviewing impurity profiles, and assessing regulatory history for any prior FDA Warning Letters or import alerts. Geographic diversity in sourcing is paramount to mitigate future single-point-of-failure risks. Companies should look beyond traditional suppliers and explore emerging markets or specialized API manufacturers who can demonstrate stringent quality control for nitrosamine impurities. This process typically involves comprehensive audits, sample testing, and regulatory documentation review, which can take several months. Business development executives should leverage this market disruption to forge new partnerships with reliable API providers, ensuring long-term supply resilience. The urgency of this recall necessitates an accelerated but thorough qualification process to safeguard patient access and maintain market share.
Cipla USA's Regulatory Compliance Record and Future Scrutiny
This Class II recall by Cipla USA, Inc. due to nitrosamine contamination will undoubtedly intensify regulatory scrutiny on the company's manufacturing facilities and quality systems. While the ChemLifeIntel Knowledge Graph does not detail a history of prior FDA Warning Letters, 483s, or Import Alerts specifically for Cipla USA, Inc. related to nitrosamine issues, this event itself marks a significant regulatory compliance challenge. The presence of N-nitroso-cinacalcet above acceptable daily intake limits points to potential deficiencies in process control, raw material qualification, or finished product testing. Regulatory affairs heads should anticipate heightened oversight from the FDA, including potential inspections of manufacturing sites involved in producing Cinacalcet Hydrochloride. This could lead to further observations (Form 483s) or even a Warning Letter if systemic issues are identified and not adequately addressed. The FDA's consistent focus on nitrosamine impurities across various drug classes means that any company experiencing such a recall will face rigorous demands for root cause analysis, corrective and preventive actions (CAPA), and verification of effectiveness. Business development executives must consider the potential reputational damage and the impact on future product approvals or market access, as a compromised compliance record can deter partners and customers. Proactive engagement with the FDA, transparent communication, and a robust remediation plan will be crucial for Cipla USA, Inc. to restore regulatory confidence and mitigate long-term commercial repercussions.
Forward Outlook: Cipla's Remediation and Market Repercussions
The ongoing Class II recall of Cipla USA's Cinacalcet Hydrochloride Tablets necessitates a comprehensive remediation strategy from the company to address the root cause of the N-nitroso-cinacalcet impurity. Cipla USA, Inc. is expected to conduct a thorough investigation into how the nitrosamine impurity formed or was introduced into Lot 5PB0183, implementing robust corrective and preventive actions (CAPA). This will likely involve re-evaluating raw material specifications, optimizing manufacturing processes, and enhancing analytical testing methods for nitrosamine detection. The FDA will closely monitor Cipla's response and the effectiveness of its remediation efforts. Failure to adequately address the underlying CGMP deviations could lead to further regulatory actions, including potential import alerts for manufacturing facilities supplying the U.S. market, which would severely impact global supply chains. For procurement directors, this means a continued need for vigilance and diversification of sourcing. Supply chain VPs should model potential future disruptions and build contingency plans. Business development executives must assess the competitive landscape, as other manufacturers of Cinacalcet Hydrochloride may gain market share due to this recall. The broader industry will continue to face pressure to implement stringent nitrosamine risk assessment and control strategies, as evidenced by general regulatory scrutiny on product quality, including events like Essential Wellness Pharma's sterility failure or Amgen's market challenges. This incident reinforces the dynamic and demanding nature of pharmaceutical regulatory compliance.